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SBF2Abstract Charcot–Marie–Tooth disease type 4B2 with early-onset glaucoma (CMT4B2, OMIM
604563) is a genetically-heterogeneous childhood-onset neuromuscular disorder. Here, we report
the case of a 15-year-old male adolescent with lower extremity weakness, gait abnormalities, foot
deformities and early-onset glaucoma. Since clinical diagnosis alone was insufﬁcient for providing
pathogenetic evidence to indicate that the condition belonged to a consanguineous family, we
applied whole-exome sequencing to samples from the patient, his parents and his younger brother,
assuming that the patient’s condition is transmitted in an autosomal recessive pattern. A frame-shift
mutation, c.4571delG (P.Gly1524Glufs*42), was revealed in the CMT4B2-related gene SBF2 (also
known asMTMR13, MIM 607697), and this mutation was found to be homozygous in the proband
and heterozygous in his parents and younger brother. Together with the results of clinical diagnosis,
this case was diagnosed as CMT4B2. Our ﬁnding further demonstrates the use of whole-exome
sequencing in the diagnosis and treatment of rare diseases.Introduction
Determination of the pathogenesis of inherited diseases is a
challenging endeavor because of the large number of known
and unknown factors involved, although some causative
factors can be revealed by traditional clinical diagnosticnces and
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To date, there are only a few effective cures for genetic
diseases. For instance, some symptomatic therapies for speciﬁc
diseases such as genetic-based cholestatic disorders, Wilson’s
disease and tyrosinemia can be cured by orthotopic liver
transplantation [2].
Here, we report a case of a 15-year-old male adolescent who
initially manifested weakness in both lower limbs at the age
when he learned to walk, and then gradually developed obvious
gait abnormalities, muscle atrophy, and talipes equinovarus,
accompanied with early-onset glaucoma. The parents of the
proband are consanguineous, and he has a younger brother
aged 2 with normal phenotype. To further investigate this
inherited disease, we performed whole-exome sequencing on
the proband, his parents and younger brother, assuming that
the condition was inherited in an autosomal recessive pattern.Results
A 15-year-old male adolescent with unconﬁrmed
Charcot–Marie–Tooth disease-like symptoms
The case in question relates to a 15-year-old male adolescent.
He was born after a full-term pregnancy and caesarian section
due to fetal distress with normal Apgar score, followed by nor-
mal growth and intelligence development. His consanguineous
parents and the 2-year-old younger brother exhibited normal
phenotype. However, he presented lower extremity weakness,
gait abnormalities, foot deformities, and early-onset glaucoma,
but no complaint of obvious paresthesia, numbness or pain.
Biochemical examination showed that metabolites in urinary
and blood samples of the probands were within normal range.
In addition, his cranial MRI showed no abnormality and
karyotype analyses also appeared normal. We further per-
formed electromyography (EMG) examination on motor and
sensory nerves, and found that the current nerve conduction
velocity (NCV) and EMG ﬁnding is consistent with a primary
demyelinating motor and sensory polyneuropathy, with mod-
erate-to-severe slowing of conduction velocities and absence
of sensory nerve action potentials (SNAPs). Besides, the clini-
cal diagnosis mostly matches Charcot–Marie–Tooth disease
type 1 (CMT1). However, mutation analysis of the main gene
PMP22 of CMT1 was negative. Therefore, the exact cause of
the condition remains unclear.
CMT is a clinically and genetically heterogeneous group of
inherited motor and sensory peripheral neuropathies. In gen-
eral, this syndrome has an infantile or juvenile onset, with
motor and sensory polyneuropathy semiology and pes cavus
[3–6]. On the basis of mode of inheritance, clinical phenotypes,Table 1 Exon coverage and depth using whole-exome sequencing for t
Exome capture statistics Father
Target region (bp) 44,234,141
Raw reads 132,038,330
Raw data yield (Mb) 11,883
Mean depth of target region (·) 126.08
Coverage of target region (%) 99.40
CCDS exons (read coverage) 265,204
CCDS genes (read coverage) 18,386
Note: CCDS, Consensus Coding Sequence Dataset.electrophysiological and pathological features, CMT can be
classiﬁed into the following types: CMT1, CMT2, CMT4,
autosomal recessive (AR)-CMT2 and dominant intermediate
(DI)-CMT (Table S1). Each type can be further divided into
several subtypes, depending on the underlying causative
molecular defect. Based on the aforementioned EMG results
and primary complaints from the patient [7], we hypothesized
that this proband suffered from CMT4B2 [8–10], although idi-
opathic congenital talipes equinovarus [11] and other neuro-
muscular disorders such as spinal muscular atrophy [12]
cannot be excluded.Targeted next-generation sequencing (NGS) of the four family
members
About 265,000 exonic regions from the genomic DNA of the 4
family members were captured. On an average, 12 Gb of
sequencing data were generated from each individual, resulting
in a mean depth of more than 110 · per base per targeted
region. The coverage of the target region was over 99%
(Table 1). In total, we identiﬁed 107,122 single-nucleotide poly-
morphisms (SNPs) from the exome of the proband (Table 2) by
using SOAPsnp based on Bayes’ theorem, by ﬁltering out low-
quality mutations according to the criteria (reads < 20,
depths < 4, estimated copy number > 2 and the interval in
between < 5). Numbers and distribution of SNPs and inser-
tion-deletions (indels) of the four family members are listed in
Table 2 and Table 3, respectively. Next, we ﬁltered the SNPs
and indels according to the ﬁltering strategy as delineated in
Figure 1. Based on the initial screening criteria with variant
location and frequency 6 0.005 in dbSNP, Hapmap and 1000
Genomes Database, and mutation type, we identiﬁed 3592
SNPs and indels. The subsequent restrictive ﬁltering control
further narrowed down the list and only 542 SNPs and indels
were retained.
Identiﬁcation of a novel SBF2 mutation, c.4571delG,
in CMT4B2
Based on the family history and clinical results (Figure 2A), we
determined that the condition is transmitted in an autosomal
recessive pattern. As a result, only homozygous variations
identiﬁed in the patient were retained for further analysis, since
heterozygous variations carried by the parents demonstrated
normal phenotype. We therefore obtained 32 SNPs and indels
from 29 genes (Table S2). Among them, only the gene SBF2
was found to be related to the phenotype.
SBF2 (also called MTMR13 or DENND7B, MIM 607697)
is located on chromosome 11, base pairs 9,800,213–10,315,753.he four family members
Mother Son-case Son-control
44,131,461 44,234,141 44,234,141
143,078,102 123,878,094 156,397,584
12,877 11,149 14,076
136.35 115.18 145.29
99.41 99.41 99.05
264,392 265,247 264,808
18,335 18,386 18,381
Table 2 Detailed whole-exome sequencing data for SNPs detected in the four family members
Type Father Mother Son-case Son-control
Total number of SNPs from each member 112,238 111,822 107,122 111,669
Missense 13,246 13,221 12,748 12,748
Readthrough 92 88 86 85
Nonsense 177 155 158 157
Splice site 2798 2732 2647 2731
Synonymous-coding 10,876 10,763 10,318 10,386
50-UTR 9211 9055 8741 9040
30-UTR 3387 3421 3238 3425
Intronic 70,013 69,952 66,830 70,645
Intergenic 2438 2435 2356 2452
Homozygous 45,121 44,639 49,047 48,643
Heterozygous 67,117 67,183 58,075 63,026
Total number of SNPs from all members 154,336
Chen M et al / A Novel SBF2 Mutation in CMT Disease 223It contains 40 exons and spans over 600 kb. SBF2 encodes SET
binding factor 2, a novel inactive phosphatase of the myotu-
bularin family [8,13], which is present in various tissues such
as the cord and the peripheral nerve. Mutations in SBF2
may cause CMT with early-onset glaucoma (CMT4B2) [7].
In humans, myotubularin-related proteins (MTMRs) consti-
tute a large family with 14 members and have been suggested
to work in phosphoinositide-mediated signaling events that
may also convey the control of myelination [8]. Recessive
mutations in SBF2 are typically found in patients with redun-
dant myelin loops or myelin outfoldings in sural nerve biopsies
[8]. Remarkably, our sequencing data revealed one novel
mutation, c.4571delG, in exon 34 of the SBF2 gene, which
was detected as homozygous in the proband and heterozygous
in the other three family members. This was also validated by
the Sanger sequencing method (Figure 2B). The c.4571delG
(p.Gly1524Glufs*42) of SBF2 is a frameshift deletion muta-
tion that causes a mutation in the myotubularin-like phospha-
tase domain of the protein. The deletion of a single guanine
residue at codon 1524 within exon 34 produces a frameshift
mutation, which generates a stop codon at codon 1566
(p.Gly1524Glufs*42) and results in a premature termination
codon. The parents carried this mutation in heterozygous form
and were considered obligate carriers. The proband harbored
the c.4571_4571delG in the homozygous form, while hisTable 3 Detailed whole-exome sequencing data for indels detected in t
Type Father
Total number of indels from each member 7174
Frameshift 308
CDS-indel 184
Splice site 410
50-UTR 664
30-UTR 256
Intron 5233
Promoter 35
Intergenic 84
Homozygous 2761
Heterozygous 4413
Total insertions 3223
Total deletions 3951
Insertion-coding 208
Deletion-coding 284
Total number of indels from all membersyounger brother with normal phenotype carried this mutation
in its heterozygous form. The same mutation is also inherited
from one of their consanguineous parents. The mutation was
not present in the dbSNP and 1000 Genomes Database.
The catalytically-inactive SBF2 associates with MTMR2,
which is an active lipid phosphatase also belonging to the
MTMR family. MTMR2 is found in the mutated form in
CMT4B1 [9,10]. Previous studies revealed a possible scenario
in which MTMR phosphatases play roles in regulating
endosomal trafﬁcking of phosphatidylinositol 3-phosphate
(PI(3)P) and bisphosphate PI(3,5)P2 [11,12]. However, molecu-
lar and cellular mechanisms addressing the correlation between
the catalytic activity of MTMR phosphatases and their muta-
tion in CMT4B remain to be elucidated. Our study showed that
the c.4571delG mutation generated a truncated SBF2 protein
(Figure 2C), which may disrupt the soluble and membrane-
associated protein complex formed by SBF2 and MTMR2,
leading to defects in PI(3)P and PI(3,5)P2 regulation. Because
this mutation causes a premature termination, the production
and function of the protein would be altered and such
alteration was inherited from the consanguineous parents
who carried the heterozygous deletion mutation but exhibited
normal phenotype. Therefore, we considered the homozygous
deletion mutation to be ‘‘pathogenic’’. However, to verify this
possibility, further experimental evidence would be required.he four family members
Mother Son-case Son-control
7073 7024 7352
309 289 260
175 183 212
387 380 421
631 642 637
228 247 264
5221 5149 5440
38 33 35
84 101 83
2570 2863 3275
4503 4161 4077
3218 3220 3542
3855 3804 3810
217 206 229
267 266 243
11,502
344 shared indels
437 SNPs 105 indels
30 SNPs
SNP
Father Mother Son-case Son-control Total
11,502
154,336112,238 111,822 107,122 111,669
7174 7073 7024
3248 shared SNPs
One frameshift mutation in SBF2
---Suspicious causative mutation
Reserve: 
Frequency ≤ 0.05 or none
Filter out: 
None, ref, intron, promoter and intergenic 
2 indels
Restrictive filtering and quality control
Homozygous in the proband
and heterozygous in his parents
Genes associated with phenotypes
7352Indel
Figure 1 Bioinformatic analysis pipeline for whole-exome sequencing data in the current study
The mutations detected by the whole-exome sequencing were ﬁltered through a series of steps. First, the low-quality mutations were
ﬁltered out (criteria: reads < 20, depths < 4, estimated copy number > 2 and the interval in between < 5). Second, the SNPs and indels
were ﬁltered based on the frequency and location mutation type. Third, candidate SNPs and indels were further ﬁltered considering the
database frequency and mutation types by adopting the pedigree analysis procedures developed in house (only 542 SNPs and indels were
retained). Finally, we took into account the inheritance mode and phenotype and the candidate gene SBF2 was found to be related to the
phenotype. None in SNP category indicate that the mutation was detected in the SOAPsnp but was ﬁltered out at the ﬁrst step, whereas
none in indel category indicate lack of indel in the tested sample. Ref indicates identity with the reference sequence. Intergenic, intron and
promoter indicate that SNP or indel is located in the intergenic region, intron or promoter region, respectively.
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Here we describe a novel mutation of the CMT-associated
gene SBF2 in a Chinese patient. CMT is a clinically and genet-
ically heterogeneous group of inherited motor and sensory
peripheral neuropathies, with a prevalence of 17–40 per
100,000 inhabitants [14,15]. In general, this syndrome has an
infantile or juvenile onset, with motor and sensory polyneu-
ropathy semiology and pes cavus [3–6]. Mendelian segregation
in families may follow either autosomal dominant, autosomal
recessive or X-linked patterns. Many previous studies have
shown that molecular genetics can be used in the typing of
CMTs such as autosomal dominant and X-linked inheritance
[16]. It is now used in case of rarer types of CMTs, such as
CMT4 with autosomal recessive pattern, that are similar to
CMT1 with dominant forms, but are usually more severe with
an earlier onset age [17,18]. According to autosomal recessive
inheritance and both axonal and demyelinating neuropathies,CMT4 can be differentiated from other forms of CMT. Nerve
conduction velocities in these individuals are often below
40 m/s. The affected individuals exhibit the typical CMT
phenotype of distal muscle weakness and atrophy associated
with sensory loss, and frequently, pes cavus foot deformity.
These individuals tend to present these symptoms at earlier
ages and with more severe disease progression, although many
CMT4 subtypes exist with extensive clinical overlap [13,19–21].
Up till now, 9 genes associated with CMT4 subtypes have
been discovered: GDAP1 (CMT4A), MTMR2 (CMT4B1),
SBF2 (CMT4B2), SH3TC2 (CMT4C), NDRG1 (CMT4D),
EGR2 (CMT4E), PRX (CMT4F), FGD4 (CMT4H) and
FIG4 (CMT4J) [22]. These subtypes can be differentiated
through clinical features, ethnic background and neuropatho-
logical features. However, most of these subtypes can only be
differentiated through genetic tests. For instance, CMT4B1 is
caused by mutations in the gene encoding MTMR2 on chro-
mosome 11q22 [23–25], and mutations in the SBF2 gene have
III
I-1 I-2
II-1 II-2 II-3 II-4
A
B
Mother
Father
Son-case
Son-control
Reference sequence
C
uDENNWT SBF2
1 86 116 298 351 420 871 957 1101 1588 1735 1849
uDENNMutant SBF2
1 86 116 298 351 420 871 957 1101 1565
GRAM MyotubularinDENN dDENN
Gly1524Glu
GRAM MyotubularinDENN dDENN PH
Figure 2 Pedigree diagram of the family
A. The proband (II-1, Son-case) showed clinical manifestations,
but not his consanguineous parents (I-1, Father; I-2, Mother) and
younger brother (II-3, Son-control). II-2 and II-4 were subjected to
active abortion. B. Diagonal arrow indicates the SBF2 c. 4571del;
the proband carried c. 4571delG, a 1-bp deletion in exon 34 of
SBF2 in homozygous form; his parents and younger brother
carried this mutation in the heterozygous form. The GenBank
accession number for the reference sequence is NG_008074.1. C.
Schematic representation of wild type and the potential mutated
SBF2 protein. The c. 4571delG deletion causes amino acid change
at codon 1524 (Gly1524Glu), leads to the frame shift onward and
thus creates a stop codon at codon 1566 (p.Gly1524Glufs*42). This
premature termination may result in a truncated SBF2 protein
product comprising 1565 amino acid residues or lack of expression
due to the nonsense-mediated decay. The gray box represents the
42 C-terminal missense-mutated residues including the Gly1524-
Glu mutation. DENN, differentially expressed in neoplastic versus
normal cells; uDENN, upstream DENN; dDENN, downstream
DENN. Myotubularin indicates the myotubularin-like phospha-
tase domain. PH, pleckstrin homology domain.
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present, there are still no effective cures for CMT4; however,
we can administer symptomatic treatments by the neurologist,physiatrist and orthopedic surgeon, such as special shoes for
foot drop correction and walking assistance, surgery for severe
pes cavus, exercise for recovery, and symptomatic treatments
for pain, depression and other symptoms [4,27–29].
In this study, we detected 32 homozygous mutations in 29
genes in a patient with unconﬁrmed CMT disease-like symp-
toms and the homozygous deletion mutation c.4571delG in
CMT4B2-related gene SBF2 was considered pathogenic. Our
protein domain organization analysis suggests that the
c.4571delG mutation introduces a premature stop codon,
which, if homozygous, may result in the loss of gene expression
due to the nonsense-mediated decay or production of a trun-
cated SBF2 protein lacking pleckstrin homology (PH) domain.
The PH domain is present in more than 100 cellular signaling
proteins, e.g., protein kinases and GTPases, and characteristi-
cally binds to proteins such as phosphatidylinositol within bio-
logical membranes [30]. It plays multiple roles in navigating
proteins to different types of host membranes and recruiting
them to appropriate subcellular compartments. In addition,
PH domains are believed to bind to the heterotrimeric Gbc
protein complex: G protein, protein kinase C and small GTP-
ases [31]. However, it appears that PH domains, despite shar-
ing low-sequence homology and non-conserved protein
function, have a conserved core structurally composed of seven
b-strands and one C-terminal a-helix [32]. Here, our ﬁnding of
the SBF2 c.4571delG mutant may introduce the possibility of
disruption or dysfunction of SBF2-MTMR2 complex forma-
tion, which may, in turn, alter PI(3)P and PI(3,5)P2 regulation
due to the PH domain deletion. Several studies also showed
that SBF2 was identiﬁed as the disease-causing gene of
CMT4B1 and CMT4B2 by molecular cloning [8,13,33]. Non-
sense or splice-site mutations affecting the N-terminus part
of the SBF2 protein have been identiﬁed in patients with
CMT4B2 [13,34]. Irregular myelin structure (outfolding) is a
characteristic sign of CMT4B2, and the mutations reported
in this study may result in nonfunctional proteins. In addition,
studies found that mutations of SBF2 can lead to thrombocy-
topenia [35], pancreatic adenocarcinoma [36] and hereditary
neuropathies [8] as well.
NGS has signiﬁcantly facilitated genome analysis. Whole-
exome genome sequencing (WES) of all protein-coding DNA
is well justiﬁed as an efﬁcient strategy to search for alleles
underlying rare Mendelian disorders [19]. Protein-coding genes
constitute only approximately 1% of the human genome, but
harbor 85% genetic mutations that determine disease-related
traits. In contrast to the laborious approach of SNP homozy-
gosity mapping, the exome sequencing approach is more time-
saving, is independent from shared allelic heritage and can be
done in the presence of allelic heterogeneity [37]. When WES
was initially introduced, its utility was highly debated, with
respect to high cost, incomplete coverage of exome and low
sensitivity for structural variation. However, WES will likely
be employed much more commonly in the future because of
the practical advantages of the technology [38]. In addition
to being applied in the diagnosis of Mendelian disorders,
WES can also be used in the analysis of complex diseases, such
as Parkinson’s disease, hypertension and autism, and will be
helpful for individualized medical treatments [39].
In summary, we found a novel frameshift mutation,
c.4571delG(P. Gly1524Glufs*42), in the SBF2 gene, which
likely leads to the CMT4B2 in the proband. Furthermore,
our study shows that whole-exome sequencing can provide fast
226 Genomics Proteomics Bioinformatics 12 (2014) 221–227and accurate sequencing information for clinic diagnosis.
Therefore, when a genetic disorder is strongly suspected, even
in the case when traditional clinical genetic testing has difﬁ-
culty in making a deﬁnite diagnosis, the application of NGS
should be considered. This approach, together with continuing
improvement of sequencing technology, allows medical
genomics to be a routine diagnostic method for rare Mendelian
disorders in the near future.
Materials and methods
Blood samples
According to the institutional ethical procedures, the periphe-
ral blood samples of the proband, his parents and younger
brother were obtained with their informed consents.
DNA extraction
Genomic DNA was extracted from 200 ll of peripheral
venous blood by standard procedures using Qiamp Blood
DNA mini Kit (Qiagen, Hilden, Germany) as instructed by
the manufacturer. DNA integrity was evaluated by 2%
agarose gel electrophoresis. All DNA samples were stored at
20 C after analysis with NanoDrop.
Whole-exome sequencing
Whole-exome sequencing was carried out using the SeqCap EZ
Human Exome Library v3.0 (64 M). Prior to sequencing, 3 lg
of qualiﬁed genomic DNA from each sample was randomly
fragmented to 200–300 bp in size on a Covaris Acoustic Sys-
tem, followed by end-repair, A-tailing and pair-end index adap-
ter ligation. The adapter-ligated templates were puriﬁed using
AgencourtAM Pure SPRI beads and ampliﬁed by 4 cycles of
ligation-mediated PCR (LM-PCR): 2 min at 94 C; 4 cycles
of 10 s at 94 C, 30 s at 62 C and 30 s at 72 C; followed by
5 min extension at 72 C. LM-PCR products were hybridized
to the SeqCap EZ Oligo pool for enrichment. After the hybrid-
ized fragments were bound to the streptavidin beads in 24 h,
non-hybridized fragments were removed. Next, captured LM-
PCR products were ampliﬁed by PCR (2 min at 98 C; 15 cycles
of 10 s at 98 C, 30 s at 60 C and 30 s at 72 C; then 5 min at
72 C), and analyzed using the Agilent 2100 Bioanalyzer and
quantitative PCR to estimate the enrichment magnitude. The
captured library was sequenced using Illumina HiSeq2000
Analyzers. We conducted 90 cycles per read to generate
paired-end reads and 8 bp of the index tag following standard
sequencing protocols from the manufacturer.
Sanger sequencing
Mutations identiﬁed by whole-exome sequencing were vali-
dated by Sanger sequencing. Primers ﬂanking the candidate
loci were designed based on reference genomic sequences of
the Human Genome from GenBank in NCBI [GenBank ID:
reference GRCh37(hg19)] and were synthesized by Invitrogen
(Shanghai, China). PCR ampliﬁcation was carried out using
ABI 9700 Thermal Cycler with the primers (sense 50-GGAC
TCCTCTTGTGCATTCTG-30 and antisense 50-GATAGACTGCTGGCTGCTTAG-30). Subsequently, all PCR products
were sequenced on ABI PRISM 3730 automated sequencer
(Applied Biosystems). Genomic sequence data analysis was
performed by DNASTAR SeqMan.
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